Can ENTRESTO use pay-for-performance schemes and patient monitoring services to justify its anticipated budget impact in the U.S.?

Novartis’ recently approved ENTRESTO impressed regulators with stellar clinical outcomes, including a 20% reduction in the risk of cardiovascular death and hospitalization and a 16% improvement in overall survival compared to the standard-of-care ACE inhibitor therapy enalapril. ENTRESTO is expected to change the management of heart failure with reduced ejection…

Big Partnerships for Big Data in Healthcare

Big data has made a serious impression in healthcare. A slew of recent announcements have recently come from some of the biggest healthcare organisations, many of them involving collaborations with major players in technology: IBM’s Watson is poised to partner with Apple, Johnson & Johnson, and Medtronic on a number…

THOUGHT PIECE PREVIEW: Alternative Access Pathways: A Bridge to the Future?

Innovation marches on with breakneck speed as oncology products with novel approaches to stopping cancer cruise through regulatory pathways on their way to FDA approval.  However, the gap between FDA approval and EMA approval, as well as the subsequent local reimbursement / pricing assessment can create major disturbances to patient…

Page 1 of 212